Working collaboratively with patients, families, and patient advocates.
Dicerna is committed to supporting the needs of patients, families, and patient advocates by providing disease education materials, resources for connecting with patient communities and support groups, and updates on current development programs.
What is RNAi?
RNA interference (RNAi) is a biologic process in which certain double-stranded RNA molecules inhibit the expression of disease-causing genes by destroying the messenger RNAs (mRNAs) of those genes. It reflects a new approach in the development of specific and powerful therapies to treat rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular disease. RNAi has the potential to treat these diseases by silencing some of the most well-validated, yet previously inaccessible drug targets.
Learn more about RNAi by clicking here.
Dicerna is using RNAi to develop therapies to address unmet medical needs in diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Our lead GalXC product candidate, DCR-PHXC, is in Phase 1 development for the treatment of patients with primary hyperoxaluria.
Learn more about Dicerna’s growing pipeline by clicking here.